Sennosides, USP 17.2 MG Oral Tablet — RxCUI 602802
RxNorm drug concept · Semantic clinical drug
RxCUI 602802
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
4 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI602802
Official nameSennosides, USP 17.2 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assennosides 17.2 MG Oral Tablet
FDA products mapped1
Package NDCs mapped4
Reported Medicaid activity (SDUD)1,604 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Senna: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Senna typically produces a bowel movement within 6 to 12 hours. That's why most people take it at bedtime — so it can do its job overnight and you get results in the morning. If no...
- How long does it take for senna to work?
- Senna is designed for short-term, occasional use. You should not use it for more than 1 week unless your doctor specifically tells you it's okay. Using laxatives too often or for t...
- Laxatives like senna can affect how your body absorbs other medications. To be safe, take senna at least 2 hours before or after any other drugs you use. It's always a good idea to...
🕸️ Concept Web — How Sennosides, USP 17.2 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Sennosides, USP 17.2 MG Oral Tablet
RxCUI 602802 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Sennosides, USP
36387IN
-
Sennosides, USP
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Senokot
202961BN
-
Senokot
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sennosides, USP Oral Tablet
373859SCDF -
Sennosides, USP Oral Product
1159068SCDG -
Sennosides, USP Pill
1159069SCDG -
Sennosides, USP Oral Tablet [Senokot]
705972SBDF -
Senokot Oral Product
1178946SBDG -
Senokot Pill
1178947SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Sennosides, USP Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sennosides, USP 17.2 MG
602801SCDC -
Sennosides, USP 17.2 MG Oral Tablet [Senokot]
1039965SBD -
Sennosides, USP 17.2 MG [Senokot]
1039964SBDC
-
Sennosides, USP 17.2 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sennosides, USP 17.2 MG
SCDC · 602801 -
Sennosides, USP Oral Tablet
SCDF · 373859 -
Sennosides, USP Oral Product
SCDG · 1159068 -
Sennosides, USP Pill
SCDG · 1159069
Brand-Name Concepts
-
Sennosides, USP 17.2 MG Oral Tablet [Senokot]
SBD · 1039965 -
Sennosides, USP 17.2 MG [Senokot]
SBDC · 1039964 -
Sennosides, USP Oral Tablet [Senokot]
SBDF · 705972 -
Senokot Oral Product
SBDG · 1178946 -
Senokot Pill
SBDG · 1178947 -
Senokot
BN · 202961
📦 FDA Products & Package NDCs
1 product · 4 package NDCs
4 package NDCs map to RxCUI 602802 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 67618-0120-06 | 36 TABLET, FILM COATED in 1 BOTTLE (67618-120-06) | Senokot | Atlantis Consumer Healthcare, Inc. | 1988-09-01 |
| 67618-0120-12 | 1 BLISTER PACK in 1 CARTON (67618-120-12) / 12 TABLET, FILM... | Senokot | Atlantis Consumer Healthcare, Inc. | 1988-09-01 |
| 67618-0120-72 | 2 CARTON in 1 PACKAGE (67618-120-72) / 1 BOTTLE in 1 CARTON... | Senokot | Atlantis Consumer Healthcare, Inc. | 2024-01-01 |
| 67618-0120-73 | 72 TABLET, FILM COATED in 1 BOTTLE (67618-120-73) | Senokot | Atlantis Consumer Healthcare, Inc. | 2025-11-15 |
Observed labelers:
Atlantis Consumer Healthcare, Inc. (4)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.4163
Range $0.4163–$0.4163
· middle 50% $0.4163–$0.4163
· 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.